Acute Agitation and Aggression Treatment Market: Introduction

According to the report, the global acute agitation and aggression treatment market was valued at US$ 4.10 Bn in 2020 and is projected to expand at a CAGR of 5.1% from 2021 to 2031. Agitation can be defined as excessive motor or verbal behavior, which can further escalate to aggression. Physical agitation and aggression are manifested in the form of throwing objects toward people, and verbal agitation and aggression manifests as abuses and threats. Acute agitation and aggression are the common symptoms of mental illnesses such as schizophrenia, dementia, bipolar disorder, alcohol withdrawal, and depression.

Changing attitude toward diagnosis of agitation and aggression among mentally ill patients and rise in awareness about treatments is the key factor projected to drive the global acute agitation and aggression treatment market during the forecast period.

Request A Sample: https://www.transparencymarketresearch.com/sample/sample.php?flag=S...

North America held major share of the global acute agitation and aggression treatment market in 2020. Focus on spreading awareness about treatment related to agitation and aggression among people, increase in economic burden of mental illness, well-established healthcare infrastructure, presence of leading players, and rise in focus of these players on research & development boost the growth of the market in North America.

The acute agitation and aggression treatment market in Asia Pacific is expected to expand at a CAGR of 6.1% from 2021 to 2031. Growth of the market in the region can be attributed to increase in the geriatric population, rise in prevalence of mental illnesses such as schizophrenia & bipolar disorder, and focus of market players on India and Japan to exploit opportunities in the emerging markets.

Increase in Incidence of Dementia in Geriatric Population to Drive Market

Dementia is a condition, which results in decline in memory and other cognitive functions, affecting daily functioning. This condition is more common among the geriatric population. According to the WHO, dementia is expected to affect 82 million people in 2030 and 152 million people in 2050 globally. According to Alzheimer’s Association Report, an estimated 5.8 million people in the U.S. aged 65 and over lived with Alzheimer's disease in 2020. The number of people aged 65 and older with Alzheimer’s dementia is projected to reach 13.8 million by 2050 owing to increase in the geriatric population. Agitation and aggression are considered the most common symptoms experienced by dementia patients. Therefore, increase in incidence of dementia among the geriatric population is likely to boost the growth of the global acute agitation and aggression treatment during the forecast period.

Request Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=B...

Pharmacologic Approaches (Drugs) Held Major Share of Global Market

In terms of treatment approach, the global acute agitation and aggression treatment market has been classified into behavioral approaches, environmental interventions, and pharmacologic approaches (drugs). The pharmacologic approaches (drugs) segment has been split into lorazepam, chlorpromazine, quetiapine, droperidol, olanzapine, ziprasidone, and others. The pharmacologic approaches (drugs) segment dominated the global market in 2020. In emergency care settings, pharmacological approach reduces agitation or aggressive behavior without causing excessive sedation, and ideally avoid invasive administration routes. Traditionally, the following classes of medications have been used to treat agitation: first-generation antipsychotics (FGAs), benzodiazepines (BZDs), and second-generation antipsychotics (SGAs). The growth of the segment can be attributed to the effectiveness of these drugs in controlling agitation and aggression.

Preference for Oral Route for Acute Agitation and Aggression Treatment

Based on route of administration, the global acute agitation and aggression treatment market has been categorized into oral, intramuscular, and others. The oral segment dominated the global acute agitation and aggression treatment market in 2020, and the trend is anticipated to continue during the forecast period. The growth of the segment can be attributed to the preference for oral medications for the treatment of agitation and aggression

Schizophrenia Dominated Global Market

In terms of indication, the global acute agitation and aggression treatment market has been segregated into schizophrenia, dementia, bipolar disorder, depression, drug-induced agitation & aggression, alcohol withdrawal, and others. The schizophrenia segment accounted for major share of the global acute agitation and aggression treatment market in 2020. The segment’s dominance can be attributed to the availability of approved drugs for the treatment of agitation in schizophrenia.

Enquiry Before Buying: https://www.transparencymarketresearch.com/sample/sample.php?flag=E...

Hospitals & Ambulatory Surgical Centers to be Major End-user

Based on end-user, the global acute agitation and aggression treatment market has been divided into hospitals & ambulatory surgical centers, psychiatric care facilities, and others. The hospitals & ambulatory surgical centers segment accounted for a major share of the global acute agitation and aggression treatment market in 2020. The segment is projected to be driven by increase in mental illness patient visits for emergency treatment.

North America to Dominate Global Market; Asia Pacific to Offer Significant Opportunities

In terms of region, the global acute agitation and aggression treatment market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is projected to account for a prominent share of the global acute agitation and aggression treatment market during the forecast period. Significant investments by the market players in research & development leading to a strong pipeline of drugs for the treatment of agitation in mental illness are the major factors driving the market in North America.

The market in Europe is anticipated to expand at a high CAGR in the near future, owing to significant number of non-government organizations focused on spreading awareness about the treatment for mental illness. For instance, the Alzheimer’s Society in the U.K., a charity organization that creates campaigns to spread awareness about the signs of agitation and aggression in Alzheimer’s, funds research efforts to find a cure for the disease in the region.

Request for covid19 Impact Analysis: https://www.transparencymarketresearch.com/sample/sample.php?flag=c...

The acute agitation and aggression treatment market in Asia Pacific is expected to grow at a rapid pace in the near future. This can be attributed to increase in the geriatric population, rise in prevalence of mental illness such as schizophrenia and bipolar disorder, and focus of market players on India and Japan to exploit opportunities in the emerging markets.

Growth Strategies of Key Players

Key players operating in the global acute agitation and aggression treatment market are Eli Lilly and Company, Pfizer, Inc., GlaxoSmithKline, Otsuka Holdings Co., Ltd., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, and H. Lundbeck A/S, Sun Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., Bausch Health Companies, Inc., Apotex, Inc., and Aurobindo Pharma. These companies engage in research & development to develop novel products in order to expand product offerings and customer base. For instance, in April 2021, Otsuka and Lundbeck announced a decision to continue a phase III clinical trial of Brexpiprazole for the treatment of agitation in patients with Alzheimer's-type dementia.

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/collagen-market-to-advance...;

https://www.globenewswire.com/news-release/2022/02/28/2392829/0/en/...

https://www.globenewswire.com/news-release/2022/03/07/2397835/0/en/...

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.